Androgen Therapy

Phase 3Small molecule

AAlliance for Clinical Trials in Oncology

Androgen Therapy is one of 43 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Prostate CancerActive, not recruiting

Castration-Sensitive Prostate CarcinomaRecruiting

Metastatic Prostate CancerPhase 3

Active, not recruiting

Castration-Sensitive Prostate CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

269 competitors in Metastatic Prostate Cancer

#DrugCompanyPhaseTrials

Xtandi

Astellas

Phase 3

18 2

Taxotere

AAvyxa

Phase 3

43 3

Erleada

Johnson & Johnson

Phase 3

15 4

Zoladex

AstraZeneca

Phase 3

7 5

Nubeqa

Bayer

Phase 3

7 6

Jevtana

Sanofi

Phase 3

7 7

Rayos

RRoxane Laboratories

Phase 3

20 8

Zometa

Pfizer

Phase 3

4 9

Prolia

Amgen

Phase 3

2 10

Medrol

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2039

Phase 3Recruiting

Castration-Sensitive Prostate Carcinoma

NCT06931340

Clinical

Trials by Indication[1]

Castration-Sensitive Prostate Carcinoma1 trial

Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)

Recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT06931340·1,260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Androgen Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Androgen Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Androgen Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alliance for Clinical Trials in Oncology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAlliance for Clinical Trials in Oncology

Androgen Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2039

Trials by Indication[1]

Castration-Sensitive Prostate Carcinoma1 trial

References

Drug Info

Quick Facts

Related News